Advanced search
Publication Cover
OncoImmunology Volume 10, 2021 - Issue 1
Submit an article Journal homepage
1,660
Views
6
CrossRef citations to date
0
Altmetric
Author’s View

An independent predictor of poor prognosis in locally advanced rectal cancer: rs867228 in formyl peptide receptor 1 (FPR1)

Shu-Fen Chianga Laboratory of Precision Medicine, Ministry of Health & Welfare Feng Yuan Hospital, Taichung, TaiwanORCID Iconhttps://orcid.org/0000-0002-0371-2658View further author information
ORCID Icon,
Kevin Chih-Yang Huangb Department of Biomedical Imaging and Radiological Science, China Medical University, Taichung, Taiwan;c Translation Research Core, China Medical University Hospital, China Medical University, Taichung, TaiwanORCID Iconhttps://orcid.org/0000-0002-0266-3233View further author information
ORCID Icon,
William Tzu-Liang Chend Department of Colorectal Surgery, Hsinchu China Medical University Hospital, Hsinchu, Taiwan;e School of Medicine, China Medical University, TaichungTaiwan;f Department of Colorectal Surgery, China Medical University Hospital, China Medical University, Taichung, TaiwanView further author information
,
Tsung-Wei Cheng Graduate Institute of Biomedical Science, China Medical University, Taichung, Taiwan;h Department of Pathology, Asia University Hospital, Asia University, Taichung, TaiwanView further author information
,
Tao-Wei Kef Department of Colorectal Surgery, China Medical University Hospital, China Medical University, Taichung, Taiwan;i School of Chinese Medicine, China Medical University, Taichung, TaiwanCorrespondence[email protected]
View further author information
&
K. S. Clifford Chaoe School of Medicine, China Medical University, TaichungTaiwan;g Graduate Institute of Biomedical Science, China Medical University, Taichung, Taiwan;j Cancer Center, China Medical University Hospital, China Medical University, Taichung, TaiwanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-7162-2566View further author information
ORCID Icon
Article: 1926074 | Received 29 Apr 2021, Accepted 01 May 2021, Published online: 14 May 2021

References

  • Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, Becker H, Raab HR, Villanueva MT, Witzigmann H, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30(16):1926–3. doi:10.1200/JCO.2011.40.1836.
  • Ryan EJ, Creavin B, Sheahan K. Delivery of personalized care for locally advanced rectal cancer: incorporating pathological, molecular genetic, and immunological biomarkers into the multimodal paradigm. Front Oncol. 2020;10:1369. doi:10.3389/fonc.2020.01369.
  • Frey B, Rubner Y, Kulzer L, Werthmoller N, Weiss EM, Fietkau R, Gaipl US. Antitumor immune responses induced by ionizing irradiation and further immune stimulation. Cancer Immunol Immunother. 2014;63(1):29–36. doi:10.1007/s00262-013-1474-y.
  • Hernandez C, Huebener P, Schwabe RF. Damage-associated molecular patterns in cancer: a double-edged sword. Oncogene. 2016;35(46):5931–5941. doi:10.1038/onc.2016.104.
  • Krombach J, Hennel R, Brix N, Orth M, Schoetz U, Ernst A, Schuster J, Zuchtriegel G, Reichel CA, Bierschenk S, et al. Priming anti-tumor immunity by radiotherapy: dying tumor cell-derived DAMPs trigger endothelial cell activation and recruitment of myeloid cells. Oncoimmunology. 2019;8(1):e1523097. doi:10.1080/2162402X.2018.1523097.
  • Huang CY, Chiang SF, Ke TW, Chen TW, Lan YC, You YS, Shiau AC, Chen WT, Chao KSC. Cytosolic high-mobility group box protein 1 (HMGB1) and/or PD-1+ TILs in the tumor microenvironment may be contributing prognostic biomarkers for patients with locally advanced rectal cancer who have undergone neoadjuvant chemoradiotherapy. Cancer Immunol Immunother. 2018;67(4):551–562. doi:10.1007/s00262-017-2109-5.
  • Vacchelli E, Le Naour J, Kroemer G. The ambiguous role of FPR1 in immunity and inflammation. Oncoimmunology. 2020;9(1):1760061. doi:10.1080/2162402X.2020.1760061.
  • Wenzel-Seifert K, Seifert R. Functional differences between human formyl peptide receptor isoforms 26, 98, and G6. Naunyn Schmiedebergs Arch Pharmacol. 2003;367(5):509–515. doi:10.1007/s00210-003-0714-7.
  • Dorward DA, Lucas CD, Chapman GB, Haslet C, Dhaliwal K, Rossi AG. The role of formylated peptides and formyl peptide receptor 1 in governing neutrophil function during acute inflammation. Am J Pathol. 2015;185(5):1172–1184. doi:10.1016/j.ajpath.2015.01.020.
  • Vacchelli E, Ma Y, Baracco EE, Sistigu A, Enot DP, Pietrocola F, Yang H, Adjemian S, Chaba K, Semeraro M, et al. Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. Science. 2015;350(6263):972–978. doi:10.1126/science.aad0779.
  • Chiang SF, Huang KC, Chen WT, Chen TW, Ke TW, Chao KSC. Polymorphism of formyl peptide receptor 1 (FPR1) reduces the therapeutic efficiency and antitumor immunity after neoadjuvant chemoradiotherapy (CCRT) treatment in locally advanced rectal cancer. Cancer Immunol Immunother. 2021. doi:10.1007/s00262-021-02894-8.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.